Gamifant
Country: Եվրոպական Միություն
language: ֆիններեն
source: EMA (European Medicines Agency)
PAR
(PAR)
19-03-2021
documentation_request_body
documentation_request_send
documentation_request_send
active_ingredient:
Emapalumab
MAH:
Swedish Orphan Biovitrum AB (publ)
ATC_code:
L04AA39
INN:
emapalumab
therapeutic_area:
Immune System Diseases
therapeutic_indication:
Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH).
authorization_status:
Refused
